ProteoSys AG innovation in functional proteomics
home contact technology fee for
service
track
record
company publications cooperation
 
NRG 101
PSY 130/131
ANXA3
NRG 101 – a protein therapeutic for CNS diseases

The problem:

Current therapies in major CNS diseases such as Alzheimer’s disease or Parkinson’s disease are perceived to be inefficient and clearly not disease-modifying.

The objective:

Development of a mechanism-based innovative pharmaceutic principle with the potential to overcome weaknesses of current treatments.

The approach:

At the beginning of the last decade, ProteoSys had already identified an isoform of Neuregulin 1, which was shown to be associated with learning and memory. When it became clear that this molecule is able to cross the blood-brain-barrier, the way towards a protein therapy seemed to open, at least in principle. The neuroprotective properties of NRG 101 were then demonstrated in various animal models, supported by independent data concerning human pathology and genetic variants, and finally by a proteomic investigation of the mode of action. Favourable results have been achieved for models of Alzheimer's disease, schizophrenia, and especially Parkinson's disease.

The result:

Today we have clear evidence that NRG 101 is a neurotrophic factor with disease modifying potential in models for Parkinson's disease that crosses the blood-brain-barrier through a receptor mediated transport to reach its target(s) in the brain.

NRG 101 will be developed to treat Parkinson’s disease – Mind-NRG [find_out_more]